News

24/10/14
Stallergenes continues its international expansion with the opening of an affiliate in Canada.

                   ...

[more]
23/10/14
Stallergenes sales reach €45.7 million in Q3 2014; Oralair® achieves market leadership in France; Continued expansion of international markets (up 33%)

                   ...

[more]

Follow us on :

STALLERGENES, A GLOBAL ALLERGY PLAYER


Stallergenes is a global pharmaceutical company with leading innovation, provider of allergy solutions all around the world. 

Stallergenes’ comprehensive approach to allergic diseases includes a complete portfolio combining diagnosis products and treatments and a new generation of allergen immunotherapy treatments.